Measuring the reversal of mtDNA damage levels is an innovative and readily available tool to measure LRRK2 kinase inhibition as a potential pharmacodynamic biomarker in clinical studies, and might have broader applications that extend to other PD-modifying drugs. This evidence concerns the gene LRRK2 and Parkinson disease.